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A 58-year-old man presented to the emergency department with a 1-month history of 
progressive, severe left hip pain that had become unbearable. The pain was constant 
and significantly worse with weight-bearing, and the patient was now confined to 
bed. He denied back pain, falls, or trauma.  
 
Although hip pain is a common complaint, and a frequent manifestation of chronic 
degenerative joint disease, the debilitating and subacute nature of the pain suggests a 
potentially more serious underlying cause. Patients and even clinicians may refer to “hip 
pain” when the actual symptoms are periarticular, often presenting over the trochanter 
laterally, or muscular, presenting as posterior pain. The true hip joint is located in the 
anterior hip and groin area and often causes symptoms that radiate to the buttock. Pain can 
also be referred to the hip area from the spine, pelvis, or retroperitoneum, so it is crucial not 
to restrict the differential diagnosis to hip pathology.  
 
Key diagnostic considerations include (1) inflammatory conditions such as trochanteric 
bursitis or gout; (2) bacterial infection of the hip joint, adjacent bone, or a nearby structure; 
(3) benign nerve compression (such as meralgia paresthetica); and (4) tumor (particularly 
myeloma or metastatic disease to the bone, but also potentially a pelvic or spinal mass with 
nerve compression). Polymyalgia rheumatica and other systemic rheumatologic complaints 
are a consideration, but since a single joint is involved, these conditions are less likely. The 
hip would be an unusual location for a first gout flare, and the duration of symptoms would 
be unusually long for gout. Avascular necrosis should be considered if the patient has 
received glucocorticoids for his previously diagnosed rheumatologic disease. If the patient 
is anticoagulated, consideration of spontaneous hematoma is reasonable, but usually this 
would present over a course of days, not weeks. The absence of trauma makes a fracture of 
the hip or pelvis less likely, and the insidious progression of symptoms makes a pathologic 
fracture less likely. 
 
The patient reported 6 months of worsening proximal upper and lower extremity 
myalgia and weakness, with arthralgia of the hips and shoulders. The weakness was 
most notable in his proximal lower extremities, although he had remained 
ambulatory until the hip pain became limiting. He maintained normal use of his arms. 
The patient denied current rash but noted photosensitivity and a mild facial rash 
several months earlier. He described having transient mouth sores intermittently for 
several years.  He denied fever, chills, night sweats, weight loss, dyspnea, recent 
travel, and outdoor exposures. Several months previously, he had been evaluated for 
these symptoms at another institution and given the diagnoses of rheumatoid 
arthritis (RA) and systemic lupus erythematosus (SLE). At that time, he had initiated 
treatment with weekly dosing of methotrexate and etanercept. 
 
The patient’s medical history was also notable for hypertension, Graves’ disease 
treated previously with radioiodine ablation, quiescent ulcerative colitis, and 
depression. Current medications included methotrexate, etanercept, levothyroxine, 
enalapril, hydrochlorothiazide, fluoxetine, ibuprofen, and oxycodone-
acetaminophen. He denied tobacco, alcohol, and recreational drug use.  
 
Weakness occurring in the proximal lower extremities is the classic distribution for 
polymyositis and dermatomyositis. In contrast to polymyalgia rheumatica, dermatomyositis 
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and polymyositis do not generally feature severe muscle pain, but they can be associated 
with a painful polyarthritis. Oral ulcers, photosensitivity, and facial rash are consistent with 
SLE, but dermatomyositis can also lead to a symmetrical erythema of the eyelids (commonly 
referred to as a “heliotrope rash,” named after the flower bearing that name) and 
sometimes can be associated with photosensitivity. Oral ulcers, particularly the painful ones 
known as “canker sores,” are extraordinarily common in the general population, and 
patients and providers may miss the mucosal lesions of SLE since they are usually painless. 
As methotrexate and etanercept are immunosuppressive, opportunistic pathogens such as 
typical or atypical mycobacteria and disseminated fungal infections should be considered 
with special attention to the possibility of infection in or near the left hip. Given that SLE 
and RA rarely coexist, it would be helpful to seek outside medical records to know what the 
prior serologic evaluation entailed, but it is unlikely that this presentation is a manifestation 
of a diffuse connective tissue process. 
 
Physical examination should focus on the features of dermatomyositis including heliotrope 
rash, truncal erythema, and papules over the knuckles (Gottron’s papules); objective 
proximal muscle weakness in the shoulder and hip girdle; and findings that might suggest 
antisynthetase syndrome such as hyperkeratotic “mechanic hand” palmar and digital 
changes and interstitial crackles on lung exam. If necrotic skin lesions are found, this would 
raise concern for a disseminated infection. The joints should be examined for inflammation 
and effusions.  
 
His temperature was 36.6° Celsius, heart rate 74 beats per minute, blood pressure 
134/76 mmHg, respiratory rate 16 breaths per minute, and O2 saturation 97% on 
room air. He was obese but did not have moon facies or a buffalo hump. There were 
no rashes or mucosal lesions. Active and passive motion of his left hip joint elicited 
pain with both flexion/extension and internal/external rotation. Muscle strength was 
limited by pain in the left hip flexors and extenders, but was 5/5 in all other muscle 
groups. Palpation of the proximal muscles of his arms and legs did not elicit pain. His 
extremities were without edema, and examination of his shoulders, elbows, wrists, 
hands, knees, ankles, and feet did not reveal any erythema, synovial thickening, 
effusion, or deformity. Examination of the heart, chest, and abdomen was normal.  
 
Given th  reassuring strength examination, the absence of rashes or skin lesions, and the 
reassuring joint exam aside from the left hip, a focal infectious, inflammatory, or malignant 
process seems most likely. The pain with range of motion of the hip does not definitively 
localize the pathology to the hip joint since pathology of the nearby structures can lead to 
pain when the hip is moved. Laboratory evaluation should include a complete blood count 
to screen for evidence of infection or marrow suppression, complete metabolic panel, and 
creatine kinase (CK). The history of ulcerative colitis raises the possibility of an enthesitis 
(inflammation of tendons or ligaments) occurring near the hip. Enthesitis is sometimes a 
feature of the seronegative spondyloarthropathy-associated conditions and can occur in the 
absence of sacroiliitis or spondyloarthropathy. 
 
The patient’s myalgias and arthralgias had recently been evaluated in the 
Rheumatology Clinic. Laboratory evaluation from that visit was remarkable only for 
an antinuclear antibody (ANA) test that was positive at a titer of 1:320 in a 
homogeneous pattern, creatine phosphokinase 366 IU/L (normal range [NR] 38-240), 
and alkaline phosphatase 203 IU/L (NR 30-130). All of the following labs from that 
visit were within normal ranges: Cyclic citrullinated peptide, rheumatoid factor, anti-
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double stranded DNA, aldolase, complement levels, serum and urine protein 
electrophoresis, thyroglobulin antibody, thyroid microsomal antibody, thyroid-
stimulating hormone (TSH), erythrocyte sedimentation rate (10 mm/hr), and C-
reactive protein (0.3 mg/dL).  
 
The patient was admitted to the hospital. Initial blood test results on admission 
included sodium 139 mEq/L, potassium 3.9 mEq/L, chloride 105 mEq/L, bicarbonate 
27 mEq/L, urea nitrogen 16 mg/dL, creatinine 0.6 mg/dL, glucose 85 mg/dL, calcium 
9.2 mg/dL (NR 8.8-10.3), phosphate 1.3 mg/dL (NR 2.7-4.6), albumin 4.7 g/dL (NR 
3.5-4.9), and alkaline phosphatase 195 IU/L (NR 30-130). The remainder of a 
comprehensive metabolic profile, CBC with differential, and coagulation studies were 
all normal.  
 
The homogeneous ANA titer of 1:320 is high enough to raise eyebrows, but is nonspecific 
for lupus and other ANA-associated rheumatologic conditions, and may be a red herring, 
particularly given the low likelihood of a systemic inflammatory process explaining this 
new focal hip pain. The alkaline phosphatase is only mildly elevated and could be of bone or 
liver origin. The reassuringly low inflammatory markers are potentially helpful, since, if 
checked now and substantially increased from the prior outpatient visit, would be 
suggestive of a new inflammatory process.  However, this would not point to a specific 
cause of inflammation.  
 
Given the focality of the symptoms, imaging is warranted. As opposed to plain films, 
contrast-enhanced computed tomography (CT) of the pelvis or magnetic resonance imaging 
(MRI) may be an efficient first step, since there is low suspicion for fracture and high 
suspicion for an inflammatory, neoplastic, or infectious process. MRI is more expensive and 
usually cannot be obtained as rapidly as CT. There is a chance that CT imaging alone will 
provide enough information to guide the next diagnostic steps, such as aspiration of an 
abscess or joint or biopsy of a suspicious lesion. But for soft tissue lesions and many bone 
lesions, including osteomyelitis, MRI offers better delineation of pathology.  
 
CT scan of the left femur demonstrated a large lytic lesion in the femoral neck that 
contained macroscopic fat and had an aggressive appearance with significant 
thinning of the cortex. MRI confirmed these findings and demonstrated a non-
displaced subtrochanteric femur fracture in the proximity of the lesion (Figure 1). 
Contrast-enhanced CT scans of the thorax, abdomen, and pelvis revealed no other 
neoplastic lesions. Prostate specific antigen level was normal. The patient’s 
significant hypophosphatemia persisted with levels dropping to as low as 0.9 mg/dL 
despite aggressive oral phosphate replacement. 
 
While hypophosphatemia is often a nonspecific finding in hospitalized patients and is 
usually of little clinical importance, profound hypophosphatemia that is refractory to 
supplementation suggests an underlying metabolic disorder. Phosphate levels less than 1.0 
mg/dL, particularly if prolonged, can lead to decreased adenosine triphosphate (ATP) 
production and subsequent weakness of respiratory and cardiac muscles. Parathyroid 
hormone (PTH) excess and production of parathyroid hormone-related protein (PTHrP) by 
a malignancy can cause profound hypophosphatemia, but are generally associated with 
hypercalcemia, a finding not seen in this case. Occasionally, tumors can lead to renal 
phosphate wasting via non-PTH related mechanisms. The best characterized example of this 
is the paraneoplastic syndrome “oncogenic osteomalacia” caused by tumor production of a 
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fibroblast growth factor. Tumors that lead to this syndrome are usually benign 
mesenchymal tumors. This patient’s tumor may be of this type, causing local destruction 
and metabolic disturbance. The next step would be consultation with orthopedic surgery for 
resection of the tumor and total hip arthroplasty with aggressive perioperative repletion of 
phosphate. Assessment of intact PTH, ionized calcium, 24-hour urinary phosphate 
excretion, and even PTHrP levels may help to rule out other etiologies of 
hypophosphatemia, but given that surgery is needed regardless, it might be reasonable to 
proceed to the operating room without these diagnostics. If the phosphate levels return to 
normal postoperatively, then the diagnosis is clear and no further metabolic testing is 
needed. 
 
PTH level was 47 pg/mL (NR 10-65), 25-hydroxyvitamin D level was 25 ng/mL (NR 
25-80), and 1,25-dihydroxyvitamin D level was 18 pg/mL (NR 18-72). Urinalysis was 
normal without proteinuria or glucosuria. A 24-hour urine collection contained 1,936 
mg of phosphate (NR 400-1200). The ratio of maximum rate of renal tubular 
reabsorption of phosphate to glomerular filtration rate (TmP/GFR) was 1.3 mg/dL 
(NR 2.4-4.2). Tissue obtained by CT-guided needle biopsy of the femoral mass was 
consistent with a benign spindle cell neoplasm. 
 
With normal calcium levels, the PTH level is appropriate, and hyperparathyroidism is 
excluded. The levels of 25-hydroxyvitamin D and 1-25-dihydroxyvitamin D are not low 
enough to suggest that vitamin D deficiency is driving the impressive hypophosphatemia. 
What is impressive is the phosphate wasting demonstrated by the 24-hour urine collection, 
consistent with paraneoplastic overproduction of fibroblast growth factor 23 (FGF23) by 
the benign bone tumor. Overproduction of this protein can be detected by blood tests or 
staining of the tumor specimen, but surgery should be performed as soon as possible 
independent of any further test results. Once the tumor is resected, phosphate metabolism 
should normalize. 
 
FGF23 level was 266 RU/mL (NR < 180). The patient was diagnosed with tumor-
induced osteomalacia (TIO). He underwent complete resection of the femoral tumor 
as well as open reduction and internal fixation of the fracture. After surgery, his 
symptoms of pain and subjective muscle weakness improved, his serum phosphate 
level normalized, his need for phosphate supplementation resolved, and his blood 
levels of FGF23 decreased into the normal range (111 RU/mL). The rapid 
improvement of his symptoms after surgery suggested that they were related to TIO, 
and not manifestations of SLE or RA. His immunosuppressant medications were 
discontinued. Surgical pathology demonstrated a heterogeneous tumor consisting of 
sheets of uniform spindle cells interspersed with mature adipose tissue. This was 
diagnosed descriptively as a “benign spindle cell and lipomatous neoplasm” without 
further classification. Two months later, the patient was ambulating without pain, 




TIO is a rare paraneoplastic syndrome affecting phosphate and vitamin D metabolism, 
leading to hypophosphatemia and osteomalacia1. TIO is caused by the inappropriate tumor 
secretion of the phosphatonin hormone, fibroblast growth factor 23 (FGF23).  
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The normal physiology of FGF23 is illustrated in Figure 2. Osteocytes appear to be the 
primary source of FGF23, but the regulation of FGF23 production is not completely 
understood. FGF23 production may be influenced by several factors, including 1,25 
dihydroxyvitamin D levels, and serum phosphate and PTH concentrations. This hormone 
binds to the FGF receptor and its coreceptor, Klotho2, causing two major physiological 
effects.  First, it decreases the expression of the sodium-phosphate co-transporters in the 
renal proximal tubular cells3,4, resulting in increased tubular phosphate wasting. This effect 
appears to be partly PTH dependent5. Second, it has effects on vitamin D metabolism, 
decreasing renal production of activated vitamin D3,4,6. 
 
In overproduction states, the elevated FGF23 leads to chronically low serum phosphate 
levels (with renal phosphate wasting) and the clinical syndrome of osteomalacia, 
manifested by bone pain, fractures, and deformities. Hypophosphatemia can also lead to 
painful proximal myopathy, cardio-respiratory dysfunction, and a spectrum of 
neuropsychiatric findings. The clinical findings in TIO are similar to those seen in genetic 
diseases in which hypophosphatemia results from the same mechanism3,4.  
 
In this case, measurement of the serum phosphate level was important in reaching the 
diagnosis. Although hypophosphatemia in the hospitalized patient is often easily explained, 
severe or persistent hypophosphatemia requires a focused evaluation. Causes of 
hypophosphatemia are categorized in Table 17,8,9. In patients with hypophosphatemia that is 
not explained by the clinical situation (e.g., osmotic diuresis, insulin treatment, refeeding 
syndrome, post-parathyroidectomy, chronic diarrhea), measurement of serum calcium, 
PTH, and 25-hydroxyvitamin D are used to investigate possible primary or secondary 
hyperparathyroidism. In addition, low-normal or low serum 1,25-dihydroxyvitamin D with 
normal PTH, normal 25-hydroxyvitamin D stores, and normal renal function are clues to the 
presence of TIO. Urine phosphate wasting can be measured by collecting a 24-hour urine 
sample. Calculation of the TmP/GFR (a measure of the maximum tubular resorption of 
phosphate relative to the glomerular filtration rate), as described by the nomogram of 
Walton and Bijvoet, may improve the accuracy of this assessment and confirm a renal 
source of the hypophosphatemia10.  
 
The patient presented here had inappropriate urinary phosphate losses, and laboratory 
testing ruled out primary and secondary hyperparathyroidism and Fanconi Syndrome. The 
patient was not taking medications known to cause tubular phosphate wasting. The 
patient’s age and clinical history made hereditary syndromes unlikely. Therefore, the 
urinary phosphate wasting had to be related an acquired defect in phosphate metabolism. 
The diagnostic characteristics of TIO are summarized in Table 2. 
 
The presence of a known neoplasm makes the diagnosis of TIO considerably easier. 
However, osteomalacia often precedes the tumor diagnosis. In these cases, the discovery of 
this clinical syndrome necessitates a search for the tumor. The tumors can be small, occult, 
and often located in the extremities. In addition to standard cross-sectional imaging, 
specialized diagnostic modalities can be helpful in localizing culprit tumors. These include 
F-18 flourodeoxyglucose positron emission tomography with computed tomography (FDG-
PET CT), 111-Indium octreotide single photon emission CT (SPECT)/ CT, 68-Gallium-DOTA-
octreotide PET/CT, and even selective venous sampling for FGF23 levels1,11. The octreotide 
tests capitalize on the fact that culprit tumors often express somatostatin receptors. 
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TIO is most often associated with mesenchymal tumors of the bone or soft tissue. It has also 
been reported in association with several malignancies (small cell carcinoma, hematologic 
malignancies, prostate cancer), and with polyostotic fibrous dysplasia, neurofibromatosis, 
and the epidermal nevus syndrome. The mesenchymal tumors are heterogeneous in 
appearance and can be variably classified as hemangiopericytomas, hemangiomas, 
sarcomas, ossifying fibromas, granulomas, giant cell tumors, or osteoblastomas1. However, 
one review suggests that most of these tumors actually represent a distinct but 
heterogeneous, under-recognized entity that is best classified as a “phosphaturic 
mesenchymal tumor11.”    
 
TIO is only cured by complete resection of the tumor1. Local recurrences have been 
described, as have rare occurrences of metastatic disease1,12. Medical treatment can be used 
to normalize serum phosphate levels in patients who are unable to be cured by surgery. The 
goal is to bring serum phosphate into the low-normal range via phosphate supplementation 
(typically 1-3 g/day of elemental phosphorus is required) and treatment with either 
calcitriol or alfacalcidiol. Due to the inhibition of 1,25-dihydroxyvitamin D activation in TIO, 
relatively large doses of calcitriol are needed. A reasonable starting dose of calcitriol is 1.5 
mcg/day, and most patients require 15-60 ng/kg per day. Because PTH action is involved in 
FGF23-mediated hypophosphatemia, suppression of PTH may also be useful in these 
patients13.  
 
This patient presented with a painful femoral tumor in the setting of muscle and joint pain 
that had been erroneously attributed to connective tissue disease. However, recognition 
and thorough evaluation of the patient’s hypophosphatemia led to a unifying diagnosis of 
TIO. This diagnosis altered the surgical approach (emphasizing complete resection to 





• Hypophosphatemia, especially if severe or persistent, should not be dismissed 
as an unimportant laboratory finding. A focused evaluation should be 
performed to determine the etiology.  
• In patients with unexplained hypophosphatemia, the measurement of serum 
calcium, parathyroid hormone, and vitamin D levels can identify primary or 
secondary hyperparathyroidism.  
• The differential diagnosis of hypophosphatemia is narrowed if there is clinical 
evidence of inappropriate urinary phosphate wasting (i.e., urinary phosphate 
levels remain high, despite low serum levels). 
• Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused 
by FGF23, a phosphatonin hormone that causes renal phosphate wasting, 
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Figure 1. Coronal T1-weighted MR image of the femoral mass. There is a nonspecific, heterogeneous, fat-
containing lesion within the femoral neck and intertrochanteric region. The bright areas (red arrow), 
suppressed on STIR images, are consistent with fat.  The nondisplaced, subtrochanteric fracture, better 
observed on other cuts, is seen as a fine lucency (blue arrow).  
95x117mm (96 x 96 DPI)  
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Figure 2. Summary of normal FGF23 physiology. FGF23 is produced by bone osteocytes, and its production 
is stimulated by serum phosphate and 1,25 (OH)2 vitamin D. FGF23 has 2 major actions at the level of the 
kidney:  1.) It downregulates the sodium-phosphate co-transporter (NaPi-2a) in the distal convoluted 
tubule.  2.) It downregulates the production of 1,25 (OH)2 vitamin D by 1 alpha-hydroxylase. In addition, 
FGF23 is thought to decrease active 1,25 (OH)2 vitamin D by inducing renal Cyp24a1, the enzyme that 
deactivates 1,25 (OH)2 vitamin D (not shown).  The resulting phosphaturia and decreased intestinal 
absorption of phosphate lead to lower serum phosphate concentrations.  Klotho is a cofactor that increases 
receptor affinity for FGF23.  
PO4 = phosphate, Ca = calcium, FGF23 = fibroblast growth factor 23  
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Insulin or catecholamine effect (including that related to refeeding syndrome, and infusion of 
glucose or TPN) 
Acute respiratory alkalosis    
Accelerated bone formation or rapid cell proliferation (e.g., hungry bone syndrome, leukemic 
blast crisis, erythropoietin or granulocyte colony stimulating factor administration) 
 
Decreased absorption 
Poor intake (including that seen in alcoholism*) 
Vitamin D deficiency 
Gastrointestinal losses (e.g., chronic diarrhea) 
Malabsorption (e.g., phosphate-binding antacids ) 
 
Urinary losses 
Osmotic diuresis (e.g., poorly controlled diabetes, acetazolamide) or volume expansion 
Other diuretics: thiazides, indapamide 
Hyperparathyroidism  
 Primary 
 Secondary (including vitamin D or calcium deficiency) 
Parathyroid hormone-related peptide 
Renal tubular disease  
Medications (e.g., ethanol*, high-dose glucocorticoids, cisplatin, bisphosphonates, 
estrogens, imatinib, acyclovir) 
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Medications inducing Fanconi Syndrome: tenofovir, cidofovir, adefovir, 
aminoglycosides, ifosfamide, tetracyclines, valproic acid 
  Other  (e.g., post-renal transplant) 






 Parenteral iron administration 
 
*Alcoholism causes hypophosphatemia via multiple mechanisms, including poor 
intake/absorption, internal redistribution, and renal effects.  
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Table 2: Diagnostic features of tumor-induced osteomalacia
1 
 
Patients may present with symptoms of osteomalacia (e.g., bone pain, fractures), 
hypophosphatemia (e.g., proximal myopathy), and/or neoplasm 
Hypophosphatemia with urinary phosphate wasting 
Serum calcium level is usually normal 
Serum 1,25-dihydroxyvitamin D level is usually low or low-normal 
Parathyroid hormone is usually normal  
Plasma FGF23 level is elevated 
A neoplasm with the appropriate histology is identified (although the osteomalacia syndrome 
may precede identification of the tumor, which may be occult) 
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